Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats

• Published in: Molecules (Basel, Switzerland) Switzerland), 2021-08, Vol.26 (16), p.5094
• Main Authors: Kamaruddin, Nurjannatul Naim, Hajri, Nor Azwin, Andriani, Yosie, Abdul Manan, Aina Farahiyah, Tengku Muhammad, Tengku Sifzizul, Mohamad, Habsah
• Format: Article
• Language: English
• Subjects: Acanthaster planci; Alanine Transaminase - blood; Animals; Arteriosclerosis; Aspartate Aminotransferases - blood; Atherosclerosis; Biocompatibility; Cancer; Cardiovascular diseases; Cell Death; Cell growth; Cell Proliferation; Chemical compounds; Cholesterol; Cholesterol - blood; Cholesterol, LDL - blood; Cytotoxicity; Enzymes; Gene expression; Hep G2 Cells; Hepatocytes; Humans; In vivo methods and tests; Invertebrates; LDL-cholesterol; LDL-receptor; Liver; Low density lipoprotein; Luciferases - metabolism; Lysosomes; Male; Marine invertebrates; Metabolism; Metabolites; Methanol; Natural products; Oxalic acid; PCSK9; PCSK9 Inhibitors; Pharmacology; Prescription drugs; Promoter Regions, Genetic - genetics; Proprotein Convertase 9 - genetics; Proprotein Convertase 9 - metabolism; Pyruvic acid; Rats; Rats, Sprague-Dawley; Starfish - chemistry; Thymidine - pharmacology; Transaminase; Transaminases; Transcription; Transfection; Triglycerides - blood; Veins & arteries
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26165094

Atherosclerosis is the main cause of cardiovascular diseases which in turn, lead to the highest number of mortalities globally. This pathophysiological condition is developed due to a constant elevated level of plasma cholesterols. Statin is currently the widely used treatment in reducing the level of cholesterols, however, it may cause adverse side effects. Therefore, there is an urgent need to search for new alternative treatment. PCSK9 is an enzyme responsible in directing LDL-receptor (LDL-R)/LDL-cholesterols (LDL-C) complex to lysosomal degradation, preventing the receptor from recycling back to the surface of liver cells. Therefore, PCSK9 offers a potential target to search for small molecule inhibitors which inhibit the function of this enzyme. In this study, a marine invertebrate , was used to investigate its potential in inhibiting PCSK9 and lowering the levels of cholesterols. Cytotoxicity activity of on human liver HepG2 cells was carried out using the MTS assay. It was found that methanolic extract and fractions did not exhibit cytotoxicity effect on HepG2 cell line with IC values of more than 30 µg/mL. A compound deoxythymidine also did not exert any cytotoxicity activity with IC value of more than 4 µg/mL. Transient transfection and luciferase assay were conducted to determine the effects of on the transcriptional activity of PCSK9 promoter. Methanolic extract and Fraction 2 (EF2) produced the lowest reduction in PCSK9 promoter activity to 70 and 20% of control at 12.5 and 6.25 μg/mL, respectively. In addition, deoxythymidine also decreased PCSK9 promoter activity to the lowest level of 60% control at 3.13 μM. An in vivo study using Sprague Dawley rats demonstrated that 50 and 100 mg/kg of methanolic extract reduced the total cholesterols and LDL-C levels to almost similar levels of untreated controls. The level of serum glutamate oxalate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) showed that the administration of the extract did not produce any toxicity effect and cause any damage to rat liver. The results strongly indicate that produced a significant inhibitory activity on PCSK9 gene expression in HepG2 cells which may be responsible for inducing the uptake of cholesterols by liver, thus, reducing the circulating levels of total cholesterols and LDL-C. Interestingly, A. planci also did show any adverse hepato-cytotoxicity and toxic effects on liver. Thus, this study strongly suggests that has a vast potential to be